MGTX MeiraGTx Holdings plc

17.4
-0.31  -2%
Previous Close 17.71
Open 17.91
Price To Book 3.27
Market Cap 636,347,963
Shares 36,571,722
Volume 167,345
Short Ratio
Av. Daily Volume 162,178
Stock charts supplied by TradingView

NewsSee all news

  1. MeiraGTx to Host Parkinson's Disease R&D Day in New York

    LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson's disease-focused

  2. MeiraGTx to Present at Upcoming Healthcare Conferences

    LONDON and NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and

  3. Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019."Following the

  4. MeiraGTx Reports Third Quarter 2019 Financial Results

    LONDON and NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended

  5. MeiraGTx to Present at Upcoming Scientific and Investor Conferences

    LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial initiation announced August 7, 2019.
AAV-AQP1
Xerostomia
Data presented at AAO October 12, 2019.
AAV-RPE65
RPE65-Deficiency
Phase 1/2 trial ongoing.
AAV-RPGR
X-Linked Retinitis Pigmentosa
Phase 1/2 trial initiation announced August 7, 2019.
AAV-CNGA3
Achromatopsia
Phase 1/2 trial ongoing.
AAV-CNGB3
Achromatopsia

Latest News

  1. MeiraGTx to Host Parkinson's Disease R&D Day in New York

    LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson's disease-focused

  2. MeiraGTx to Present at Upcoming Healthcare Conferences

    LONDON and NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and

  3. Kadmon Provides Business Update and Reports Third Quarter 2019 Financial Results

    NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (NYSE:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2019."Following the

  4. MeiraGTx Reports Third Quarter 2019 Financial Results

    LONDON and NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the quarter ended

  5. MeiraGTx to Present at Upcoming Scientific and Investor Conferences

    LONDON and NEW YORK, Oct. 03, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will present at the following

  6. MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences

    LONDON and NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company's